Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials
In the STOP-V1 and STOP-V2 trials, povorcitinib (an oral JAK1 inhibitor) was superior to placebo in improvement in F-VASI75 score in individuals with nonsegmental vitiligo.